Peroxisome proliferator-activated receptor: Effects on nutritional homeostasis, obesity and diabetes mellitus;Receptores activados por los proliferadores de peroxisomas: Implicaciones sobre la homeostasis nutricional, en la obesidad y en la diabetes mellitus

Nutricion Hospitalaria

Volumn 26, Issue 2, 2011, Pages 271-279

  Abranches, Monise Viana ^a   de Oliveira, F C Esteves ^a   Bressan, J ^b  

^a FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^b Fedral University of Viçosa   (Brazil)

Author keywords

Diabetes mellitus; Metabolism; Obesity; Peroxisome proliferator activated receptors

Indexed keywords

INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN;

ADIPOGENESIS; BIOSYNTHESIS; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DIGESTIVE SYSTEM; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; METABOLISM; MITOCHONDRION; NUTRITION; OBESITY; PATHOPHYSIOLOGY; PEROXISOME; PHYSIOLOGY; REVIEW;

ADIPOGENESIS; ADIPOSITY; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DIGESTIVE SYSTEM; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; MITOCHONDRIA; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PEROXISOMES; PROTEINS;

EID: 79955525528     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2011.26.2.4875     Document Type: Review

References (41)

1. Guri AJ, Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptors: Bridging metabolic syndrome with molecular nutrition. Clin Nutr 2006; 25 (6): 871-85.
2. Guan Y. Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome. J Am Soc Nephrol 2004; 15 (11): 2801-15.
3. Triana MH, Álvarez VR. Obesidad, una epidemia mundial. Implicaciones de la genética. Rev. Cuba Invest Biomed 2007; 26 (2): 1-10.
4. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferators-activated receptor in malignant diseases. Crit Rev Oncol/Hematol 2006; 58 (1): 1-14.
5. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 2007; 1771 (8): 952-60.
6. Zoete V, Grosdidier A, Michielin O. Peroxisome proliferatoractivated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta. 2007; 1771 (8): 915-25.
7. Desvergne B, Wahli W. Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism. Endocr Rev 1999; 20 (5): 649-88.
8. Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B et al. The peroxisome proliferators-activated receptor regulates amino acid metabolism. FASEB J 2001; 15 (11): 1971-8.
9. Cheatham WW. Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 2010; 91 (1): 262S-266S.
10. Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, Werman A, Pories WJ, Caro JF et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99 (10): 2416-22.
11. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-a in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997; 46 (8): 1319-27.
12. Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti Jr JR, Olefsky JM. Skeletal muscle Peroxisome Proliferator-Activated Receptor-RRexpression in obesity and non-insulindependent diabetes mellitus. J Clin Invest 1998; 101: 543-8.
13. Jeffcoat R. Obesity-A perspective based on the biochemical interrelationship of lipids and carbohydrates. Med Hypotheses 2007; 68 (5): 1159-71.
14. Mallordy A, Poirier H, Besnard P, Niot I, Carlier H. Evidence for transcriptional induction of the liver fatty-acid-bindingprotein gene by bezafibrate in the small intestine. Eur J Biochem 1995; 227 (3): 801-7.
15. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 1996; 137 (1): 354-66.
16. Poirier H, Niot I, Degrace P, Monnot MC, Bernard A, Besnard P. Fatty acid regulation of fatty acid-binding protein expression in the small intestine. Am J Physiol 1997; 273: G289-95.
17. Latruffe N, Cherkaoui Malki M, Nicolas-Frances V, Clemencet MC, Jannin B, Berlot JP. Regulation of the peroxisomal M-oxidation-dependent pathway by peroxisome proliferator-activated receptor rrand kinases. Biochem Pharmacol 2000; 60 (8): 1027-32.
18. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis. 2001; 21 (1): 43-55.
19. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARrrin energy metabolism and vascular homeostasis. J Clin Invest 2006; 116 (3): 571-80.
20. Minnich A, Tian N, Byan L, Bilder G. A potent PPAR22agonist stimulates mitochondrial fatty acid b-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2001; 280 (2): E270-9.
21. Sugden MC, Holness MJ. Potential role of peroxisome proliferator-activated receptor-aain the modulation of glucose-stimulated insulin secretion. Diabetes. 2004; 53 (Suppl. 1): S71-81.
22. Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J Lipid Res 2003; 44 (11): 2049-58.
23. Zandbergen F, Plutzky J. PPARrrin atherosclerosis and inflammation. Biochim Biophys Acta 2007; 1771 (8): 972-82.
24. Cabrero A, Alegret M, Sánchez RM, Adzet T, Laguna JC, Vázquez M. Bezafibrate Reduces mRNA Levels of Adipocyte Markers and Increases Fatty Acid Oxidation in Primary Culture of Adipocytes. Diabetes. 2001; 50 (8): 1883-90.
25. Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor rrand adipose tissue-understandinding obesityrelated changes in regulation of lipid an glucose metabolism. J Clin Endocrinol Metab 2007; 92 (2): 386-95.
26. Kersten S. Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 2002; 440: 223-34.
27. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K et al. PPAR gamma Mediates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance. Mol Cell 1999; 4 (4): 597-609.
28. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA et al. Comprehensive messenger ribonucleic acid profiling reveals that Peroxisome Proliferator-Activated Receptor g activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142 (3): 1269-77.
29. Spiegelman BM, Enerbäck S. The adipocyte: a multifunctional cell. Cell Metabolism 2006; 4 (6): 425-427.
30. Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 2003; 288: 1111-7.
31. Rosado EL, Monteiro J, Hernández JA, Martins MF, Cecon PR. [Effect of diet and PPARgamma2 and beta2-adrenergic receptor genes on energy metabolism and body composition in obese women]. Nutr Hosp 2006; 21 (3): 317-31.
32. Kintscher U, Law RE. PPAR3-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol 2005; 288 (2): E287-91.
33. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001; 50 (2): 411-17.
34. Guerre-Millo M, Rouault C, Poulain P, André J, Poitout V, Peters JM, et al. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 2001; 50 (12): 2809-14.
35. Holness MJ, Smith ND, Greenwood GK, Sugden MC. Acute (24 h) activation of peroxisome-proliferator-activated receptor (PPAR) alpha reverses high-fat feeding induced insulin hypersecretion in vivo and in perifused pancreatic islets. J Endocrinol 2003; 177 (3): 197-205.
36. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101 (6): 1354-61.
37. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis en tipe 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26 (1): 28-40.
38. Sugden MC, Bulmer K, Gibbons GF, Knight BL, Holness MJ. Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochem J 2002; 364: 361-8.
39. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006; 103 (9): 3444-9.
40. Wu Z, Xie Y, Morrison RF, Bucher NL, Farmer SR. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest 1998; 101 (1): 22-32.
41. Sheikh K, Camejo G, Lanne B, Halvarsson T, Landergren MR, Oakes ND. Beyond lipids, pharmacological PPAROOactivation has important effects on amino acid metabolism as studied in the rat. Am J Physiol Endocrinol Metab 2007; 55 (4): E1157-E1165.